Insider Trading Alert - PRGX, AHC And AMRI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 12, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $40.83 to $3,226,332.72.

Highlighted Stocks Traded by Insiders:

PRGX Global (PRGX) - FREE Research Report

Cole David A, who is Director at PRGX Global, bought 15,000 shares at $4.26 on March 12, 2015. Following this transaction, the Director owned 77,440 shares meaning that the stake was boosted by 24.02% with the 15,000-share transaction.

The shares most recently traded at $4.15, down $0.11, or 2.61% since the insider transaction. Historical insider transactions for PRGX Global go as follows:

  • 4-Week # shares bought: 28,600
  • 4-Week # shares sold: 23,860
  • 12-Week # shares bought: 28,600
  • 12-Week # shares sold: 23,860
  • 24-Week # shares bought: 94,600
  • 24-Week # shares sold: 23,860

The average volume for PRGX Global has been 91,600 shares per day over the past 30 days. PRGX Global has a market cap of $111.2 million and is part of the services sector and diversified services industry. Shares are down 26.4% year-to-date as of the close of trading on Thursday.

PRGX Global, Inc., together with its subsidiaries, provides recovery audit services to businesses and government agencies having payment transactions in the United States, Canada, Latin America, Europe, Asia, and the Pacific region. Currently, there is 1 analyst who rates PRGX Global a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRGX - FREE

TheStreet Quant Ratings rates PRGX Global as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full PRGX Global Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

A H Belo (AHC) - FREE Research Report

Moise Grant, who is SVP/Bus Dev & Niche Products at A H Belo, sold 2,660 shares at $8.09 on March 12, 2015. Following this transaction, the SVP/Bus Dev & Niche Products owned 1,596 shares meaning that the stake was reduced by 62.5% with the 2,660-share transaction.

The shares most recently traded at $8.03, down $0.06, or 0.75% since the insider transaction. Historical insider transactions for A H Belo go as follows:

  • 4-Week # shares bought: 1,880
  • 4-Week # shares sold: 11,228
  • 12-Week # shares bought: 1,880
  • 12-Week # shares sold: 11,228
  • 24-Week # shares bought: 1,880
  • 24-Week # shares sold: 24,262

The average volume for A H Belo has been 89,200 shares per day over the past 30 days. A H Belo has a market cap of $155.1 million and is part of the services sector and media industry. Shares are down 21.87% year-to-date as of the close of trading on Thursday.

A. H. Belo Corporation operates as a newspaper publishing, and local news and information company primarily in the United States. It owns and operates three metropolitan daily newspapers and related Web sites. The stock currently has a dividend yield of 3.99%. The company has a P/E ratio of 2.1. Currently, there are no analysts who rate A H Belo a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on AHC - FREE

TheStreet Quant Ratings rates A H Belo as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full A H Belo Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Albany Molecular Research (AMRI) - FREE Research Report

Hagen Steven R, who is SVP Manufacturing & Pharmaceut at Albany Molecular Research, sold 721 shares at $18.30 on March 12, 2015. Following this transaction, the SVP Manufacturing & Pharmaceut owned 31,641 shares meaning that the stake was reduced by 2.23% with the 721-share transaction.

The shares most recently traded at $18.74, up $0.44, or 2.35% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 41,623
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 121,623
  • 24-Week # shares bought: 60,000
  • 24-Week # shares sold: 242,623

The average volume for Albany Molecular Research has been 541,700 shares per day over the past 30 days. Albany Molecular Research has a market cap of $598.0 million and is part of the health care sector and drugs industry. Shares are up 17.2% year-to-date as of the close of trading on Thursday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The company has a P/E ratio of 152.8. Currently, there are 2 analysts who rate Albany Molecular Research a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings rates Albany Molecular Research as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full Albany Molecular Research Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null

More from Markets

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Tiffany & Co. Sees a Strong Market in Asia

Tiffany & Co. Sees a Strong Market in Asia

Imagining the Stock Market in 10 Years

Imagining the Stock Market in 10 Years

Video: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Video: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss